Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
…, WT Tai, WC Feng, CH Hsu, PJ Chen, AL Cheng - … of Pharmacology and …, 2011 - ASPET
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by the …
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by the …
Treatment of liver cancer
CY Liu, KF Chen, PJ Chen - Cold Spring …, 2015 - perspectivesinmedicine.cshlp.org
Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer.
Incidence of liver cancer varies geographically and parallels with the geographic prevalence of …
Incidence of liver cancer varies geographically and parallels with the geographic prevalence of …
Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ
…, SK Kulp, KF Chen, CS Chen, JW Huang, CS Chen - Cancer research, 2005 - AACR
Certain members of the thiazolidenedione family of the peroxisome proliferator-activated
receptor γ (PPARγ) agonists, such as troglitazone and ciglitazone, exhibit antitumor effects; …
receptor γ (PPARγ) agonists, such as troglitazone and ciglitazone, exhibit antitumor effects; …
3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells
SK Kulp, YT Yang, CC Hung, KF Chen, JP Lai… - Cancer research, 2004 - AACR
Regarding the involvement of cyclooxygenase-2 (COX-2)-independent pathways in
celecoxib-mediated antineoplastic effects, the following two issues remain outstanding: identity of …
celecoxib-mediated antineoplastic effects, the following two issues remain outstanding: identity of …
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
…, HP Huang, JW Huang, PJ Chen, KF Chen - Journal of …, 2011 - Elsevier
BACKGROUND & AIMS: Recently, we reported that sorafenib sensitizes hepatocellular
carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of …
carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of …
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular
carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein …
carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein …
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
…, YC Lin, CW Shiau, PK Li, PJ Chen, AL Cheng - Clinical cancer …, 2010 - AACR
Purpose: Recombinant tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a
promising antitumor agent. However, many hepatocellular carcinoma (HCC) cells show …
promising antitumor agent. However, many hepatocellular carcinoma (HCC) cells show …
OSU-03012, a novel celecoxib derivative, induces reactive oxygen species–related autophagy in hepatocellular carcinoma
…, WC Lee, WC Feng, CS Chen, ML Kuo, AL Cheng - Cancer research, 2008 - AACR
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause
of cancer death worldwide. Systemic treatments for HCC have been largely unsuccessful. …
of cancer death worldwide. Systemic treatments for HCC have been largely unsuccessful. …
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1–mediated inhibition of STAT3
…, CY Liu, CH Ko, MW Lin, PJ Chen, KF Chen - Molecular cancer …, 2012 - AACR
The multiple kinase inhibitor dovitinib is currently under clinical investigation for hepatocellular
carcinoma (HCC). Here, we investigated the mechanistic basis for the effects of dovitinib …
carcinoma (HCC). Here, we investigated the mechanistic basis for the effects of dovitinib …
[HTML][HTML] Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative …
…, CY Wang, CW Shiau, LM Tseng, KF Chen - Breast cancer …, 2014 - Springer
Introduction Tamoxifen, a selective estrogen receptor (ER) modulator, may affect cancer cell
survival through mechanisms other than ER antagonism. In the present study, we tested the …
survival through mechanisms other than ER antagonism. In the present study, we tested the …